Skip to main content
Log in

New Drugs for Insomnia

Comparative Tolerability of Zopiclone, Zolpidem and Zaleplon

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Insomnia affects 30–35% of people living in developed countries. The impact of insomnia on daytime functioning and its relationship with medical and psychiatric illnesses necessitate early treatment to prevent insomnia becoming persistent and to avoid the development of complications. However, pharmacological strategies must achieve a balance between sedative and adverse effects.

In the last 30 years, benzodiazepines have been the preferred drugs for the treatment of insomnia. Benzodiazepines act nonselectively at two central receptor sites, named ω1 and ω2, which are located in different areas of the CNS. The sedative action of benzodiazepines is related to ω1 receptors, whereas ω2 receptors are responsible for their effects on memory and cognitive functioning. According to their pharmacokinetic profile, benzodiazepines can be classified into three groups: short half-life (<3 hours), medium half-life (8–24 hours) and long half-life (>24 hours).

The newer non-benzodiazepine agents zopiclone, zolpidem and zaleplon have a hypnosedative action comparable with that of benzodiazepines, but they display specific pharmacokinetic and pharmacodynamic properties. These three ‘Z’ agents all share a short plasma half-life and limited duration of action. In addition, these agents are selective compounds that interact preferentially with ω1 receptors (sedative effect), whereas benzodiazepines also interact with ω2 receptors (adverse effects on cognitive performance and memory). Zaleplon is characterised by an ultrashort half-life (approximately 1 hour). Zolpidem and zopiclone have longer half-lives (approximately 2.4 and 5 hours, respectively). These properties, together with the low risk of residual effect, may explain the limited negative influences of these agents on daytime performance. Psychomotor tasks and memory capacities appear to be better preserved by non-benzodiazepine agents than by benzodiazepines. When present, cognitive deficits almost exclusively coincide with the peak plasma concentration. In particular, impairment can emerge in the first hours after drug administration, whereas psychomotor and memory tests carried out 7–8 hours later (i.e. in the morning) generally show no relevant alterations.

As with benzodiazepines, the three ‘Z’ non-benzodiazepine agents should be used for a limited period, even in chronic relapsing conditions. Further evaluation is needed of the safety of hypnosedative medications in the long-term management of insomnia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Gallup Organization. Sleep in America. Princeton (NJ): The Gallup Organization, 1991

  2. Mellinger GD, Baiter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatr 1985; 42: 225–32

    Article  PubMed  CAS  Google Scholar 

  3. Sweetwood H, Grant I, Kfipke DF, et al. Sleep disorder over time: psychiatric correlates among males. Br J Psychiatr 1980; 136: 456–62

    Article  CAS  Google Scholar 

  4. Karacan I, Thornby JI, Anch M, et al. Prevalence of sleep disturbances in a primarily urban Florida county. Soc Sci Med 1976; 10: 239–44

    Article  PubMed  CAS  Google Scholar 

  5. Kales JD, Kales A, Bixler EO, et al. Biopsychobehavioral correlates of insomnia, V: clinical characteristics and behavioral correlates. Am J Psychiatr 1984; 141: 1371–6

    PubMed  CAS  Google Scholar 

  6. Zammit GK, Weiner J, Damato N, et al. Quality of life in people with insomnia. Sleep 1999; 22Suppl. 2: 379–85

    Google Scholar 

  7. American Sleep Disorders Association. The international classification of sleep disorders: diagnostic and coding manual. Lawrence (KS): Allen Press, 1990

  8. Walsh JK, Fillingim JM. Role of hypnotic drugs in general practice. Am J Med 1990; 88: 345–85

    Article  Google Scholar 

  9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994

  10. Vaughn McCall W. A psychiatric perspective on insomnia. J Clin Psychiatr 2001; 62Suppl. 10: 27–32

    Google Scholar 

  11. Wiggs L, France K. Behavioural treatments for sleep problems in children and adolescents with physical illness, psychological problems or intellectual disabilities. Sleep Med Rev 2000: 314

    Google Scholar 

  12. Chouinard G, Lefko-Singh K, Teboul E. Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem. Cell Mol Neurobiol 1999; 19(4): 532–52

    Article  Google Scholar 

  13. Ponciano E, Freitas F, Camara J, et al. A comparison of efficacy, tolerance and residual effects of zopiclone, flurazepam and placebo in insomniac out-patients. Int Clin Psychopharmacol 1990; 5Suppl. 2: 69–77

    PubMed  Google Scholar 

  14. Billiard M, Besset A, de Lustrac C, et al. Effects of zopiclone on sleep, daytime somnolence and nocturnal and daytime performance in healthy volunteers [in French]. Neurophysiol Clin 1989; 19: 131–43

    Article  PubMed  CAS  Google Scholar 

  15. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ 2000 Jan 25; 162(2): 225–33

    PubMed  CAS  Google Scholar 

  16. Vermeeren A, Danjou PE, O’Hanlon JF. Residual effects of evening and middle-of-the-night administration of zaleplon 10mg and 20mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 1998; 13: 98–107

    Article  Google Scholar 

  17. Nicholson AN, Stone BM. Efficacy of zopiclone in middle age. Sleep 1997; 10(l): 35–9

    Google Scholar 

  18. Broadhurst A, Cushanaghan C. Residual effects of zopiclone. Sleep 1987; 10-l: 48–53

    Google Scholar 

  19. Billiard M, Besset A, De Lustrac C, et al. Dose response effects of zopiclone on night sleep and on nighttimes and daytime functioning. Sleep 1987; 10(l): 27–34

    PubMed  Google Scholar 

  20. Tamminen T, Hansen P. Chronic administration of zopiclone and nitrazepam in the treatment of insomnia. Sleep 1987; 10Suppl l: 63–72

    PubMed  Google Scholar 

  21. Elie R, Lavoie G, Bourgouin J, et al. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 1990; 5: 279–86

    Article  PubMed  CAS  Google Scholar 

  22. Bocca ML, Le Doze F, Etard O, et al. Residual effect of zolpidem 10mg and zopiclone 7.5mg versus flunitrazepam 1mg and placebo on driving performance and ocular saccades. Psychopharmacology 1999; 143(4): 373–9

    Article  PubMed  CAS  Google Scholar 

  23. Hajak G, Clarenbach P, Fisher W, et al. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 1994; 9: 251–61

    Article  PubMed  CAS  Google Scholar 

  24. Dietrich B, Emilien G, Salinas E, et al. Zaleplon does not produce residual sedation in a phase-advance model of transient insomnia [abstract]. J Sleep Res 1998; 7Suppl. 2: 67

    Google Scholar 

  25. Disayavanish C, Srisurapanont M, Disayavanish P, et al. Zopiclone in the treatment of insomnia: an open clinical test. J Med Assoc Thai 1998 Jun; 81-6: 393–6

    Google Scholar 

  26. Anderson A. Zopiclone and nitrazepam: a multicenter placebo controlled comparative study of efficacy and tolerance in 27-34 insomniac patients in general practice. Sleep 1987; 10(1): 54–62

    PubMed  Google Scholar 

  27. Bianchi M, Mush B. Zopiclone discontinuation: a review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 1990; 5(2): 45

    Google Scholar 

  28. Inman W, Kubota K, Pearl G, et al. PEM reporter number 10: zopiclone. Pharmacoepidemiol Drug Saf 1993; 2: 499–521

    Article  Google Scholar 

  29. Tiberge M, Calvet U, Khayi N, et al. Comparaison des effects de la zopiclone et du triazolam sur le sommeil du sujet sain. L’Encefale 1988; XIV: 319–24

    Google Scholar 

  30. Nakajiama T, Sasaki T, Nakagome K, et al. Comparison of the effects of zolpidem and zopiclone on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy volunteers. Life Sci 2000; 67: 81–90

    Article  Google Scholar 

  31. Jones IR, Sullivan G. Physical dependence on zopiclone: case report. BMJ 1998; 316: 317

    Google Scholar 

  32. Anyonrinde O, Sampson E. Physical dependence on zopiclone: risk of dependence may be greater in those with dependent personalities. BMJ 1998; 317: 146

    Google Scholar 

  33. Beaumont G, Holland RL. A multicenter open study in general practice to evaluate the efficacy and acceptability of zopiclone 7.5mg nocte in patients requiring the prescription of an hypnotic. Int Clin Psychopharmacol 1990; 5(l): 11–20

    PubMed  Google Scholar 

  34. Allain H, Delahaye Ch, Lecoz F, et al. Postmarketing surveillance of zopiclone in insomnia: analysis of 20,513 cases. Sleep 1991; 14(5): 408–13

    PubMed  CAS  Google Scholar 

  35. Eligulashvili TS. The effects of Imovane on sleep structure and respiratory index during sleep in insomniacs patients [abstract]. Am Vein Zh Nevropatol Psikhiat Im S S Korsakova 1997; 97(4): 50–2

    CAS  Google Scholar 

  36. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 1995; 29(3): 142–53

    Article  PubMed  Google Scholar 

  37. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64(5): 553–61

    Article  PubMed  CAS  Google Scholar 

  38. Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 1998; 61(3): 253–69

    Article  PubMed  CAS  Google Scholar 

  39. Isawa S, Suzuki M, Uchiiumi M, et al. The effects of zolpidem and zopiclone on memory. Nihon Shinkei Seishin Yakurigaku Zasshi 2000 May; 20(2): 61–9

    PubMed  CAS  Google Scholar 

  40. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000; 20(3): 328–37

    Article  PubMed  CAS  Google Scholar 

  41. Danjou P, Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2h before awakening. J Clin Pharmacol 1999; 48: 367–74

    CAS  Google Scholar 

  42. Wesensten NJ, Blankin TJ, Belenky GL, et al. Reversal of triazolam and zolpidem-induced memory impairment by flumazenil. Psychopharmacology 1995; 121: 242–9

    Article  PubMed  CAS  Google Scholar 

  43. Wesenten NJ, Blakin TJ, Belenky GL. Effects of daytime administration of zolpidem versus triazolam on memory. Eur J Clin Pharmacol 1995; 48: 115–22

    Google Scholar 

  44. Rush CR, Griffiths RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 1996; 16: 145–57

    Article  Google Scholar 

  45. Giesche R, Cluydts RJ, Dingemanse J, et al. Effects of bretazenil vs zolpidem and placebo on experimentally induced sleep disturbance in healthy volunteers. Meth Find Clin Pharmacol 1994; 16(9): 667–75

    Google Scholar 

  46. Dujardin K, Guieu JD, Lenconte-Lambert C, et al. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. Pharmacopsychiatry 1998; 31: 14–8

    Article  PubMed  CAS  Google Scholar 

  47. Mintzer MZ, Frey JM, Yingling JE, et al. Triazolam and zolpidem: a comparison of their psychomotor, cognitive, and subjective effects in healthy volunteers. Behav Pharmacol 1997 Nov; 8(6-7): 561–74

    Article  PubMed  CAS  Google Scholar 

  48. Mintzer MZ, Griffiths RR. Triazolam and zolpidem: effects on human memory and attentional processes. Psychopharmacology 1999; 144(1): 8–19

    Article  PubMed  CAS  Google Scholar 

  49. Mintzer MZ, Griffiths RR. Selective effects of zolpidem on human memory function. J Psychopharmacol 1999; 13(1): 18–31

    Article  PubMed  CAS  Google Scholar 

  50. Berlin I, Warot D, Hergurta T, et al. Comparison of the effects of zolpidem and triazolam on memory function, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993; 13: 100–6

    Article  PubMed  CAS  Google Scholar 

  51. Wesensten NJ, Blankin TJ, Belenky GL. Effects of daytime administration of zolpidem and triazolam on performance. Aviat Space Environ Med 1996 Feb; 67(2): 115–20

    PubMed  CAS  Google Scholar 

  52. Vermeeren A, O’Hanlon JF. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo. Acta Ther 1995; 21: 47–64

    Google Scholar 

  53. Hindmarch I, Stanley N, Paty I, et al. Comparison of the residual effects of zaleplon and zolpidem after administration during the night [abstract]. Eur Neuropsychopharmacol 2000; 10Suppl. 3: 394

    Article  Google Scholar 

  54. Sicard BA, Trocherie S, Moreau J, et al. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel pilot. A viat. Space Environ Med 1993; 64: 371–5

    CAS  Google Scholar 

  55. Fleming J, Moldofsky H, Walsh JK, et al. Comparison of the residual effects and efficacy of short term zolpidem, flurazepam and placebo in patients with chronic insomnia. Clin Drug Invest 1995; 9(6): 303–13

    Article  Google Scholar 

  56. Richens A, Mercer AJ, Jones DM, et al. Effects of zolpidem on saccadic eye movements and psychomotor performance: a double-blind, placebo controlled study in healthy volunteers. Br J Clin Pharmacol 1993; 36: 61–5

    Article  PubMed  CAS  Google Scholar 

  57. Hajak G, Bandelow B. Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol 1998; 13: 157–67

    Article  PubMed  CAS  Google Scholar 

  58. Ganzoni E, Santoni J, Chevillard V, et al. Zolpidem in insomnia: a 3-year post-marketing surveillance study in Switzerland. J Int Med Res 1995; 23: 61–73

    PubMed  CAS  Google Scholar 

  59. Walsh JK, Roth T, Randazzo A, et al. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2000; 23(8): 1087–96

    PubMed  CAS  Google Scholar 

  60. Volkerts ER, Verster JC, Van Heuckelum JHG, et al. The impact on car-driving performance of zaleplon or zolpidem administration during the night [abstract]. Eur Neuropsychopharmacol 2000; 10Suppl. 3: 395

    Article  Google Scholar 

  61. Sakkas P, Psarros C, Masdrakis V, et al. Dependence on zolpidem: a case report. Eur Psychiatry 1999; 14(6): 358–9

    Article  PubMed  CAS  Google Scholar 

  62. Courtet P, Pignay V, Castelnau D, et al. Abuse and dependence on zolpidem: a report of seven cases. Encephale 1999; 25(6): 652–7

    PubMed  CAS  Google Scholar 

  63. Vartzopoulos D, Bozikas V, Phocas C, et al. Dependence on zolpidem in high dose. Int Clin Psychopharmacol 2000; 15(3): 181–2

    Article  PubMed  CAS  Google Scholar 

  64. Soyka M, Bottlender R, Moller HJ. Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry 2000; 33(4): 138–41

    Article  PubMed  CAS  Google Scholar 

  65. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999; 14: 287–303

    PubMed  CAS  Google Scholar 

  66. Sanchez LGB, Sanchez JM, Moreno JLL. Dependence and tolerance with zolpidem. Am J Health-Syst Pharm 1996; 53(1): 2638

    PubMed  CAS  Google Scholar 

  67. Aragona M. Abuse, dependence, and epileptic seizures after zolpidem withdrawal: review and case report. Clin Neuropharmacol 2000; 23(5): 281–3

    Article  PubMed  CAS  Google Scholar 

  68. Monti JM, Monti D, Estevez F, et al. Sleep in patients with chronic primary insomnia during long-term zolpidem administration and after its withdrawal. Int Clin Psychopharmacol 1996; 11: 255–63

    Article  PubMed  CAS  Google Scholar 

  69. Poirrier R, Franck G, Scheldewaert R, et al. The effects of long-term zolpidem treatment on nocturnal polysomnography and daytime vigilance in patients with psychophysiological insomnia. Acta Ther 1994; 20: 77–84

    Google Scholar 

  70. Scharf MB, Roth T, Vogel GW, et al. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55: 192–9

    PubMed  CAS  Google Scholar 

  71. Monti JM, Attali P, Monti D, et al. Zolpidem and rebound insomnia: a double-blind, controlled polysomnographic study in chronic insomniac patients. Pharmacopsychiatry 1994; 27: 166–75

    Article  PubMed  CAS  Google Scholar 

  72. Herrmann WM, Kubiscki ST, Boden S, et al. Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic learned insomnia: psychometric and polysomnographic evaluation. J Int Med Res 1993; 21: 306–22

    PubMed  CAS  Google Scholar 

  73. Biondi F, Casadei GL. Results of a multicenter trial with the hypnotic zolpidem in 1152 insomniac patients. Curr Ther Res 1994 Mar; 55(3): 262–74

    Article  Google Scholar 

  74. Elko CJ, Burgess JL, Robertson WO. Zolpidem-associated hallucinations and serotonin reuptake inhibitor: a possible interaction. J Toxicol Clin Toxicol 1998; 36(3): 195–203

    Article  PubMed  CAS  Google Scholar 

  75. Lahmeyer H, Wilcox CS, Kann J, et al. Subjective efficacy of zolpidem in outpatients with chronic insomnia. Clin Drug Invest 1997; 13(3): 134–44

    Article  CAS  Google Scholar 

  76. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992; 20: 150–61

    PubMed  CAS  Google Scholar 

  77. Kummer J, Guendel L, Linden J, et al. Long term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993; 21: 171–84

    PubMed  CAS  Google Scholar 

  78. Maarek L, Cramer P, Attali P, et al. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992; 20: 162–70

    PubMed  CAS  Google Scholar 

  79. Terzano MG, Parrino L, Boselli M, et al. Sensitivity of cyclic alternating pattern to prolonged pharmacotherapy: a 5-week study evaluating zolpidem in insomniac patients. Clin Neuropharmacol 1997; 20(5): 447–54

    Article  PubMed  CAS  Google Scholar 

  80. Cluydts R, Peeters K, de Bouyalsky I, et al. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: a double-blind, randomized pilot study. J Int Med Res 1998; 26: 13–24

    PubMed  CAS  Google Scholar 

  81. Silvestri R, Ferrillo F, Murri L, et al. Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized comparison of zolpidem versus triazolam. Hum Psychopharmacol 1996; 11: 225–33

    Article  CAS  Google Scholar 

  82. Elie R, Ruther E, Farr J, et al. Zaleplon Clinical Study Group. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999; 60: 536–44

    Article  PubMed  CAS  Google Scholar 

  83. Peeters K, Boucau M, De Bouyalsky I. Efficacy and safety of one-month treatment with zolpidem in a middle-aged and elderly insomniacs. Acta Ther 1997; 23: 5–19

    CAS  Google Scholar 

  84. Cluydts RJ, Roeck DJM. Three week multicentre general practitioner study of zolpidem in 651 patients with insomnia. Acta Ther 1993; 19: 73–90

    Google Scholar 

  85. Ahrens J. Treatment of sleep disorders with zolpidem: efficacy without potential dependency [in German]. Ther Schweiz 1993; 9: 660–2

    Google Scholar 

  86. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Hum Psychopharmacol Clin Exp 1998; 13: 191–8

    Article  CAS  Google Scholar 

  87. Allard S, Sainati SM, Roth-Schechter BF, et al. Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1998; 39: 184–91

    Google Scholar 

  88. Piergies AA, Sweet J, Johnson M, et al. The effects of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Pharmacol Ther 1996; 34(4): 178–83

    CAS  Google Scholar 

  89. Markowitz JS, Pharm D, Brewerton TD. Zolpidem-induced psychosis. Ann Clin Psychiatry 1996; 8(2): 89–91

    Article  PubMed  CAS  Google Scholar 

  90. Hoyler CL, Tekell JL, Silva JA. Zolpidem-induced agitation and disorganization. Gen Hosp Psychiatry 1996; 18: 452–3

    Article  PubMed  CAS  Google Scholar 

  91. Toner LC, Tsambiras BM, Catalano G, et al. Central nervous system side effects associated with zolpidem treatment. Clin Neuropharmacol 1999; 23(1): 54–8

    Article  Google Scholar 

  92. Girault C, Mihaltan MF, Borderies P, et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD. Chest 1996 Nov; 110(5): 1203–11

    Article  PubMed  CAS  Google Scholar 

  93. Pagot R, Cramer P, L’Heritier C, et al. Comparison of the efficacy and tolerability of zolpidem 20mg and triazolam 0.5mg in anxious or depressed insomniac patients. Curr Ther Res 1993; 53(1): 88–97

    Article  Google Scholar 

  94. Cohn MA. Effects of zolpidem, codeine phosphate and placebo on respiration. Drug Saf 1993; 9(4): 312–9

    Article  PubMed  CAS  Google Scholar 

  95. Cirignotta F, Mondini S, Zucconi M, et al. Zolpidem-polysomnographic study of new hypnotic drug in sleep apnea syndrome. Pharmacol Biochem Behav 1988; 29: 807–9

    Article  PubMed  CAS  Google Scholar 

  96. Karsenti D, Blanc P, Bacq Y, et al. Hepatotoxicity associated with zolpidem treatment. BMJ 1999; 318(7192): 1179

    Article  PubMed  CAS  Google Scholar 

  97. Clarck A. Worsening hepatic encephalopathy secondary to zolpidem. J Pharm Technol 1999; 15: 139–41

    Google Scholar 

  98. Langer S, Mendelson W, Richardson G. Symptomatic treatment of insomnia. Sleep 1999; 22Suppl. 3: 437–45

    Google Scholar 

  99. Hajak G, Cluydts R, Declerk A, et al. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of a large-scale, double-blind, randomized, outpatient study. Int Clin Psychopharmacol 2002; 17: 9–17

    Article  PubMed  CAS  Google Scholar 

  100. Allain H, Arbus L, Schuck S, et al. Efficacy and safety of zolpidem administered ‘as needed’ in primary insomnia: results of a double-blind, placebo-controlled study. Clin Drug Invest 2001; 21 (6): 391–400

    Google Scholar 

  101. Krystal AD, Perlis ML, McCall WV, et al. Three-month non-nightly use of zolpidem for the treatment of primary insomnia [abstract]. Sleep 2002; 25Suppl. 2: A68

    Google Scholar 

  102. Cluydts R, Heyde K, De Volder F. Efficacy and safety of discontinuous zolpidem treatment - an exploratory polysomnographic study [abstract]. Sleep 2001 Apr; 24: A332

    Google Scholar 

  103. Weitzel KW, Wickman JM, Augustin SG, et al. Zaleplon: a pyrazolopyrimidine sedative-hypnotic agent for the treatment of insomnia. Clin Ther 2000; 22(11): 1254–67

    Article  PubMed  CAS  Google Scholar 

  104. Cada DJ, Baker DE, Levien T. Zaleplon. Hosp Pharm 2000; 35(1): 77–86

    Google Scholar 

  105. Beer B, Ieni JR, Wu WH, et al. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non benzodiazepine hypnotic. J Clin Pharmacol 1994; 34(4): 335–44

    PubMed  CAS  Google Scholar 

  106. Walsh JK, Fry J, Erwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5mg and 10mg for the treatment of primary insomnia. Clin Drug Invest 1998; 16: 347–54

    Article  CAS  Google Scholar 

  107. Allen D, Curran HV, Lader M. The effects of single doses of CL 284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993; 45: 313–20

    Article  PubMed  CAS  Google Scholar 

  108. Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000; 23(1): 17–21

    Article  PubMed  CAS  Google Scholar 

  109. Walsh JK, Vogel GW, Scharf M, et al. A five week polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia. Sleep Med 2000; 1: 41–9

    Article  PubMed  Google Scholar 

  110. Scharf M. The safety of long-term treatment of insomnia with zaleplon [abstract]. Eur Coll Neuropsych 1999; 9Suppl. 5: 360

    Article  Google Scholar 

  111. Elie R, Davignon M, Emilien G. Zaleplon decreases sleep latency in outpatients without producing rebound insomnia after 4 weeks of treatment [abstract]. J Sleep Res 1998; 7Suppl. 2: 76

    Google Scholar 

  112. Fry J, Scharf MB, Berkowitz DW, et al. A phase III, 28 day, multicenter, randomized, double-blind, comparator and placebo-controlled, parallel-group safety, tolerability, and efficacy study of 5, 10, and 20mg of zaleplon, compared with 10mg of zolpidem or placebo, in adult outpatients with insomnia [abstract]. Sleep 1998; 21Suppl.: 262

    Google Scholar 

  113. Rush CR, Frey JM, Griffiths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology 1999; 145: 39–51

    Article  PubMed  CAS  Google Scholar 

  114. Zaleplon (Sonata®) [package insert]. Philadelphia (PA); Wyeth Laboratories, 1999

  115. Bhatia SC, Arora M, Bhatia SK. Perceptual disturbances with zaleplon. Psychiatr Serv 2001; 52(1): 109–10

    Article  PubMed  CAS  Google Scholar 

  116. Parrino L, Terzano MG. Polysomnographic effects of hypnotic drugs. Psychopharmacology 1996; 126: 1–16

    Article  PubMed  CAS  Google Scholar 

  117. Dooley M, Plosker GL. Zaleplon: a review of its use in the treatment of insomnia. Drugs 2000; 60(2): 413–45

    Article  PubMed  CAS  Google Scholar 

  118. Parrino L, Smerieri A, Spaggiari MC, et al. Modifications of sleep structure in insomniac patients treated with zolpidem and zopiclone [abstract]. Sleep Res Online 1999; 2Suppl. 1: 158

    Google Scholar 

  119. Krakow B, Melendrez B, Ferreira E, et al. Prevalence of insomnia symptoms in patients with sleep-disordered breathing. Chest 2001; 120(6): 1923–9

    Article  PubMed  CAS  Google Scholar 

  120. Terzano MG, Parrino L. Clinical applications of cyclic alternating pattern. Physiol Behav 1993; 54: 807–13

    Article  PubMed  CAS  Google Scholar 

  121. Terzano MG, Parrino L. Origin and significance of the cyclic alternating pattern. Sleep Med Rev 2000; 4(1): 101–23

    Article  PubMed  Google Scholar 

  122. World Psychiatric Association. Report of the task force on sedative hypnotics. Eur Psychiatry 1993; 8: 45–9

    Google Scholar 

  123. Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16: 873–96

    PubMed  CAS  Google Scholar 

  124. Hatoum HT, Kong SX, Kania CM, et al. Insomnia, health-related quality of life and health-care resource consumption: a study of managed-care organisation enrolees. Pharmacoeconomics 1998; 14: 629–37

    Article  PubMed  CAS  Google Scholar 

  125. Dement WC, Pelayo R. Public health and treatment of insomnia. Eur Psychiatry 1997; 12Suppl. 1: 31s–9s

    Article  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no potential conflicts of interest that are directly relevant to the contents of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mario Giovanni Terzano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terzano, M.G., Rossi, M., Palomba, V. et al. New Drugs for Insomnia. Drug-Safety 26, 261–282 (2003). https://doi.org/10.2165/00002018-200326040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200326040-00004

Keywords

Navigation